Valneva secures funding to develop Chikungunya vaccine

EC approves La Jolla’s refractory hypertension treatment
Credit: Shutterstock.com/ Nixx Photography

French biotech Valneva has secured funding of up to $23.4 million as part of a new partnership with the Coalition for Epidemic Preparedness Innovations (CEPI).

The funding, provided with support from the EU’s Horizon 2020 programme, will be used to support the development of a single-dose Chikungunya vaccine.

It will also accelerate the regulatory approval of the vaccine for use in regions where outbreaks occur.

Valneva will also maintain a stockpile of the vaccine candidate and work to transfer the secondary manufacturing of the drug product to partners for lower- and middle-income countries—where outbreaks of Chikungunya have occurred—to improve access to the vaccine for at-risk populations.

The investment is part of CEPI’s third call for proposals, launched earlier this year with support from the EU’s Horizon 2020 research and innovation programme.

Since the launch of this call in January 2019, over $66 million has been invested in two Chikungunya vaccine candidates and two RVF vaccine candidates.